

## Idogen - A Cell Therapy Case Valued at a Discount

Redeye returns with an updated assessment of Idogen following the advancement of its lead project IDO 8 and the forthcoming start of its clinical phase I/IIa trial. We emphasize that the share price stands in contrast to this, currently trading at a single-digit enterprise value, offering an upside opportunity.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.

### Attachments

---

[Idogen - A Cell Therapy Case Valued at a Discount](#)